checkAd

     150  0 Kommentare Roche and Illumina partner to broaden patient access to genomic testing - Seite 3



    The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

    All trademarks used or mentioned in this release are protected by law.


    Roche Group Media Relations
    Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
    - Nicolas Dunant (Head)
    - Patrick Barth
    - Daniel Grotzky
    - Karsten Kleine
    - Nathalie Meetz
    - Barbara von Schnurbein

    Attachment

    Seite 3 von 3



    Diskutieren Sie über die enthaltenen Werte



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Roche and Illumina partner to broaden patient access to genomic testing - Seite 3 Partnership to leverage Illumina’s extensive decentralised installed base with Roche’s expertise in assay development and to provide broad access to clinical oncology next-generation sequencingComprehensive genomic testing improves clinical decision …

    Schreibe Deinen Kommentar

    Disclaimer